melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The V600E mutation of BRAF (BRAF<sup>V600E</sup>), which constitutively activates the ERK/MAPK signaling pathway, is frequently found in melanoma and other cancers.
|
31548614 |
2020 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A 39-year-old white male was treated with vemurafenib, cobimetinib, and atezolizumab for a stage IV (T0, N3, M1) BRAF-V600E mutated malignant melanoma in the context of a clinical trial.
|
31157737 |
2020 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions.
|
31791701 |
2020 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The p.V600E mutation in the BRAF protein is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi.
|
31102256 |
2020 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma.
|
31796433 |
2020 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We established vemurafenib-resistant (VR) cells from three BRAF (V600E)-mutated melanoma lines (C32, HMY-1, and SK-MEL-28) and evaluated the mechanism of acquired resistance of VR cells by water-soluble tetrazolium salts assay, western blot, real-time quantitative PCR, and immunofluorescent microscopy.
|
30920401 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF inhibitors (BRAFi) are used to treat patients with melanoma harboring the V600E mutation.
|
30482853 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
CTC profiling was performed using 5 known melanoma mRNA biomarkers and BRAF V600E DNA mutation.
|
31672856 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
By using genetic material collected noninvasively and to further validate the PLA, somatic hotspot mutations in genes known to be drivers of early melanoma development (BRAF other than V600E, NRAS, and the TERT promoter) can also be identified.
|
30500343 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
<b>:</b> The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma patients with BRAF (V600E) mutations has demonstrated significant clinical benefits.
|
31416288 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Chronic sun-damaged (CSD) melanoma represents 10%-20% of cutaneous melanomas and is characterized by infrequent BRAF V600E mutations and high mutational load.
|
31811783 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Of these inhibitors, encorafenib and binimetinib are the newest combination, which received approval by the Food and Drug Administration (FDA) for the treatment of BRAF V600E/K-mutated melanoma in June 2018.
|
31050693 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Sixty five consecutive formalin-fixed paraffin-embedded (FFPE) melanoma samples were prospectively tested for BRAF mutations with the VE1 (anti-BRAF V600E) antibody and for both BRAF and NRAS mutations with the Idylla NRAS-BRAF-EGFR S492R Mutation Assay cartridges.
|
31415669 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Targeted therapies, based on identification of common oncogenic mutations such as BRAF V600E/K and monoclonal antibody immunotherapies, have transformed the treatment of melanoma.
|
30868471 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The present study aims to assess the prevalence and prognostic significance of BRAF V600E mutation and apprehend its association with clinicopathologic features in stage I to III Turkish melanoma patients.
|
31058533 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Patients with rare <i>BRAF</i> mutations can respond to targeted therapy, however, efficacy seems to be lower compared with V600E mutated melanoma.
|
31580757 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our data suggest indoor tanning may promote melanomas that arise in skin with low-chronic sun-induced damage through BRAF V600E-mediated melanomagenesis.
|
30923800 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
B-raf V600E protein analysis revealed a subjacent layer of heterogeneity for mutation-positive metastatic melanomas.
|
31835364 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The combination of a BRAF inhibitor dabrafenib and a MEK inhibitor trametinib (CombiDT) has improved outcomes compared with chemotherapy or BRAF inhibitor monotherapy in advanced BRAF V600E/K melanoma.
|
30661097 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
To anticipate possible resistance to ERK inhibitors (ERKi), we used SCH772984 (SCH) as a model ERKi to characterize resistance mechanisms in two BRAF V600E melanoma cell lines.
|
30833419 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our results demonstrated that the BRAF V600E mutation is a frequent event in Indian melanomas, and represents an important molecular target for novel therapeutic approaches.
|
30803557 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Notorious oncogenic BRAF V600E plays a significant role in the signal transduction of the MAPK pathway, which is involved in tumor growth, especially in melanoma.
|
30630714 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A PDOX nude mouse model of a BRAF V600E-mutant melanoma was established in the chest wall of nude mice and also tested with rMETase in combination with a first-line melanoma drug, temozolomide (TEM).
|
30725414 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
This study reviews the management of BRAF-V600E mutant melanoma with ependymal involvement.
|
30972290 |
2019 |
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Vemurafenib is a B-Raf V600E inhibitor that exerts significant inhibitory effects in melanoma but not in colon cancer, and the mechanism of vemurafenib resistance remains unclear.
|
30872078 |
2019 |